SecBot SecBot

HURA

TuHURA Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001498382 Biotech & Drug Discovery
$1.96 −0.22 (−10.06%)
Oct 26 4:00 PM ET · prev $2.18
Market cap
$128.1M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$8.00
+308% · range $6.20–10.00
Next earnings
Nov 13
in 18 days · EPS est. −$0.13
1 year
−14.8%
from $2.30 · Oct 27
30 days
−6.2%
from $2.09
52-week range
$0.4400–3.15
−38% from high · low Feb 5
Avg volume 20D
314.8K
Oct 21 spike 1.08M
Short interest
6.10M
≈9.6% of shares · −2.9%
Days to cover
28.4
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 10 reports · 90 days
Balance 0 bearish · 0 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 7/10 ·Next Earnings date, Nov 13, 2026
Strongest NEUTRAL TuHURA Biosciences adopted a 2026 Inducement Equity Incentive Plan, reserving 5,000,000 shares of common…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 8 added (0 new), 16 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.130 → −$0.130 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −2.9% to 6.10M shares. 28.4 days to cover, ≈9.6% of shares.

  • TrendDOWNTREND

    4% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
NORTHERN TRUST CORPDOUBLED1,621,042$3.8M
BlackRock, Inc.TRIM690,088$1.6M
GEODE CAPITAL MANAGEMENT, LLCTRIM484,219$1.1M
STATE STREET CORPTRIM188,404$440.9K
MORGAN STANLEYDOUBLED143,257$335.2K
GOLDMAN SACHS GROUP INCADD131,768$308.3K
Bank of New York Mellon CorpTRIM121,662$284.7K
Cetera Investment AdvisersTRIM61,620$144.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +308%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 18, 2026Citizens
REITERATE
REITERATEMarket Outperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
May 28, 2026
Bianco James A.
Chief Executive Officer
GIFT150,000 sh
Feb 12, 2026
Ng George K
Director
AWARD156,240 sh
Feb 12, 2026
List Alan
Director
AWARD156,240 sh
Feb 12, 2026
MANUSO JAMES S J
Director
AWARD156,240 sh
Feb 12, 2026
Tendler Craig
Director
AWARD156,240 sh
Feb 12, 2026
Hoffman Robert E.
Director
AWARD156,240 sh

Earnings setup

Estimates
Nov 13
reports in 18 days
−$0.13
EPS estimate, this quarter
0%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.14–-$0.12+0.0%$0.00
Next Q-$0.13-$0.14–-$0.12+0.0%$0.00
Current FY-$0.53-$0.55–-$0.51-6.0%$0.00
Next FY-$0.60-$0.61–-$0.60—$13.5M

Short side

FINRA· Sep 30, 2026
6,096,015
shares short
-2.9%
vs prior settlement
28.4
days to cover
≈9.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 SEC
TuHURA Biosciences drew an additional $650,000 under its existing $50 million revolving credit facility with Parkview…
8-K — Impact 2/10
Oct 13, 2026 Other
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human
Sep 24, 2026 SEC
TuHURA Biosciences drew an additional $650,000 under its existing $50 million revolving credit facility with Parkview…
8-K — Impact 2/10
Sep 17, 2026 SEC
TuHURA Biosciences drew down an additional $650,000 from its existing $50 million revolving credit facility with…
8-K — Impact 2/10
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — DOUBLED
1,621,042 shares ($3.8M)
Jun 30, 2026 Inst.
BlackRock, Inc. — TRIM
690,088 shares ($1.6M)
May 28, 2026 Insider
Bianco James A. gifted 150,000 shares
Chief Executive Officer
Feb 12, 2026 Insider
Ng George K was granted 156,240 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 13, 2026
Earnings date
HURA Q3 2026 Earnings Scheduled — 2026-11-13
Recent
Oct 13, 2026
Press release
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies TAMPA, Fla., Oct. 13, 2026…
Oct 5, 2026
Press release
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies…
Sep 14, 2026
Press release
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company…
Sep 8, 2026
Press release
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company…
Aug 14, 2026
Earnings
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company…

SecBot reports

16 filings · 0 bullish · 2 bearish · 1 mixed · 13 neutral
All HURA filing & press-release reports (16)